Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 9/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131922 | 0.85 | RAB9A (0.49) | LMNAPKMKMT2AALDH1A1MEN1 | |
| SCHEMBL131921 | 0.85 | RAB9A (0.49) | LMNAPKMKMT2AALDH1A1MEN1 | |
| SCHEMBL130201 | 0.83 | ALDH1A1 (0.47) | LMNAKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL8775796 | 0.82 | TBXAS1 (0.61) | TBXAS1 | |
| SCHEMBL8775833 | 0.82 | TBXAS1 (0.61) | TBXAS1 | |
| SCHEMBL8327552 | 0.80 | TBXAS1 (0.54) | TBXAS1LMNAKDM4EPKMKMT2A | |
| SCHEMBL13236797 | 0.78 | L3MBTL1 (0.55) | LMNAKDM4EPKMKMT2AALDH1A1 | |
| SCHEMBL30930819 | 0.77 | L3MBTL1 (0.50) | TBXAS1LMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL15765091 | 0.77 | L3MBTL1 (0.50) | TBXAS1LMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL2422440 | 0.77 | L3MBTL1 (0.50) | TBXAS1LMNAKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132812-A1 | Oral hypoglycaemic agents | NOVO NORDISK A/S (DK) | 2002-09-19 | — | — | US | disclosed |
| WO-2002038559-A1 | 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS | NOVO NORDISK A/S (DK) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132812-A1 | Oral hypoglycaemic agents | SLC5A2, GPR119, SLC5A1 | TBXAS1 1092/4885LMNA 4855/4885KDM4E 2768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.